RecruitingNCT00353483
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
Sponsor
Washington University School of Medicine
Enrollment
300 participants
Start Date
Sep 14, 2005
Study Type
OBSERVATIONAL
Conditions
Summary
The main purpose of this study is to compare genetic markers present on tumor cells before and after chemotherapy.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study examines how chemotherapy or hormone therapy given before or after breast cancer surgery changes the biology of breast tissue, aiming to understand which treatments work best and why.
**You may be eligible if...**
- You have been diagnosed with breast cancer and are scheduled to receive chemotherapy or hormone therapy before or after surgery
- You are willing to have additional tissue samples collected during your scheduled surgery
- You are 18 years of age or older
**You may NOT be eligible if...**
- You are not receiving systemic therapy (chemotherapy or hormonal treatment) as part of your breast cancer care
- You have already completed all planned treatments
- You have a bleeding disorder or other condition that makes tissue sampling unsafe
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PROCEDUREPeripheral blood draw
PROCEDUREBreast tissue collection
PROCEDUREBone marrow biopsy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT00353483
Related Trials
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807183 locations
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700296 locations
Breast Cancer, Reasoning, and Activity Intervention
NCT048160061 location
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
NCT072222151 location
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
NCT05573893107 locations